Save Product
Product Details
Synonyms
OX40L, TNFSF4, CD252, Glycoprotein Gp34, TXGP1, CD134 ligand, CD134L
Source
Human OX40 Ligand Protein, Mouse IgG2a Fc Tag (OXL-H5250) is expressed from human 293 cells (HEK293). It contains AA Gln 51 - Leu 183 (Accession # P23510-1).
Predicted N-terminus: Gln 51
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 42.3 kDa. The protein migrates as 53-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human OX40 Ligand Protein, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA
Immobilized Human OX40, Fc Tag (Cat. No. OX0-H5255) at 0.5 μg/mL (100 μL/well) can bind Human OX40 Ligand Protein, Mouse IgG2a Fc Tag (Cat. No. OXL-H5250) with a linear range of 0.8-13 ng/mL (QC tested).
Protocol
Bioactivity-BLI
Loaded Human OX40 Ligand Protein, Mouse IgG2a Fc Tag (Cat. No. OXL-H5250) on Protein A Biosensor, can bind Human OX40, His Tag (Cat. No. OX0-H5224) with an affinity constant of 2 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Bioactivity-Flow Cytometry
FACS assay shows that recombinant Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) can bind to 293T cell overexpressing human OX40. The concentration of OX40 Ligand is 0.003 μg/ml (Routinely tested).
Protocol
FACS analysis shows that the binding of Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) to 293T overexpressing OX40 was inhibited by increasing concentration of neutralizing anti-OX40 antibody. The concentration of OX40 Ligand used is 0.002 μg/ml. IC50=3.021 μg/ml (Routinely tested).
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Drug Development Progress- English Name：
Tumor necrosis factor ligand superfamily member 4
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
13 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
